Development and Validation of a Polygenic Risk Score for Stroke in the Chinese Population

Xiangfeng Lu; Xiaoge Niu; Chong Shen; Fangchao Liu; Zhongying Liu; Keyong Huang; Laiyuan Wang; Jianxin Li; Dongsheng Hu; Yingxin Zhao; Xueli Yang; Fanghong Lu; Xiaoqing Liu; Jie Cao; Shufeng Chen; Hongfan Li; Wuzhuang Tang; Zhanyun Ren; Ling Yu; Xianping Wu; Xigui Wu; Ying Li; Huan Zhang; Jianfeng Huang; Zhibin Hu; Hongbing Shen; Cristen J Willer; Dongfeng Gu

doi:10.1212/WNL.0000000000012263

Development and Validation of a Polygenic Risk Score for Stroke in the Chinese Population

Neurology. 2021 Aug 10;97(6):e619-e628. doi: 10.1212/WNL.0000000000012263. Epub 2021 May 24.

Authors

Xiangfeng Lu¹, Xiaoge Niu², Chong Shen², Fangchao Liu², Zhongying Liu², Keyong Huang², Laiyuan Wang², Jianxin Li², Dongsheng Hu², Yingxin Zhao², Xueli Yang², Fanghong Lu¹, Xiaoqing Liu², Jie Cao², Shufeng Chen², Hongfan Li², Wuzhuang Tang², Zhanyun Ren², Ling Yu², Xianping Wu², Xigui Wu², Ying Li², Huan Zhang², Jianfeng Huang², Zhibin Hu², Hongbing Shen², Cristen J Willer², Dongfeng Gu²

Affiliations

¹ From the Key Laboratory of Cardiovascular Epidemiology and Department of Epidemiology (Xiangfeng Lu, X.N., Fangchao Liu, Z.L., K.H., L.W., J.L., J.C., S.C., H.L., Xigui Wu, Y.L., J.H., D.G.), State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Department of Epidemiology and Biostatistics (C.S., Z.H., H.S.), Center for Global Health, School of Public Health, Nanjing Medical University; Department of Biostatistics and Epidemiology (D.H.), School of Public Health, Shenzhen University Health Science Center, Guangdong; Cardio-Cerebrovascular Control and Research Center (Y.Z., Fanghong Lu), Institute of Basic Medicine, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan; Tianjin Key Laboratory of Environment, Nutrition and Public Health (X.Y.), Department of Occupational and Environmental Health, School of Public Health, Tianjin Medical University, Tianjin; Division of Epidemiology (Xiaoqing Liu), Guangdong Provincial People's Hospital and Cardiovascular Institute, Guangzhou; Department of Neurology (W.T., Z.R.), Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing; Department of Cardiology (L.Y.), Fujian Provincial Hospital, Fuzhou; Center for Chronic and Noncommunicable Disease Control and Prevention (Xianping Wu), Sichuan Center for Disease Control and Prevention, Chengdu; Center for Genetic Epidemiology and Genomics (H.Z.), School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou; Research Unit of Prospective Cohort of Cardiovascular Diseases and Cancer (H.S.), Chinese Academy of Medical Sciences (2019RU038); and Department of Internal Medicine, Division of Cardiovascular Medicine (C.J.W.), and Department of Human Genetics (C.J.W.), University of Michigan, Ann Arbor. xiangfenglu@sina.com.
² From the Key Laboratory of Cardiovascular Epidemiology and Department of Epidemiology (Xiangfeng Lu, X.N., Fangchao Liu, Z.L., K.H., L.W., J.L., J.C., S.C., H.L., Xigui Wu, Y.L., J.H., D.G.), State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing; Department of Epidemiology and Biostatistics (C.S., Z.H., H.S.), Center for Global Health, School of Public Health, Nanjing Medical University; Department of Biostatistics and Epidemiology (D.H.), School of Public Health, Shenzhen University Health Science Center, Guangdong; Cardio-Cerebrovascular Control and Research Center (Y.Z., Fanghong Lu), Institute of Basic Medicine, Shandong First Medical University (Shandong Academy of Medical Sciences), Jinan; Tianjin Key Laboratory of Environment, Nutrition and Public Health (X.Y.), Department of Occupational and Environmental Health, School of Public Health, Tianjin Medical University, Tianjin; Division of Epidemiology (Xiaoqing Liu), Guangdong Provincial People's Hospital and Cardiovascular Institute, Guangzhou; Department of Neurology (W.T., Z.R.), Affiliated Yixing People's Hospital of Jiangsu University, People's Hospital of Yixing City, Yixing; Department of Cardiology (L.Y.), Fujian Provincial Hospital, Fuzhou; Center for Chronic and Noncommunicable Disease Control and Prevention (Xianping Wu), Sichuan Center for Disease Control and Prevention, Chengdu; Center for Genetic Epidemiology and Genomics (H.Z.), School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Medical College of Soochow University, Suzhou; Research Unit of Prospective Cohort of Cardiovascular Diseases and Cancer (H.S.), Chinese Academy of Medical Sciences (2019RU038); and Department of Internal Medicine, Division of Cardiovascular Medicine (C.J.W.), and Department of Human Genetics (C.J.W.), University of Michigan, Ann Arbor.

Abstract

Objective: To construct a polygenic risk score (PRS) for stroke and evaluate its utility in risk stratification and primary prevention for stroke.

Methods: Using a meta-analytic approach and large genome-wide association results for stroke and stroke-related traits in East Asians, we generated a combined PRS (metaPRS) by incorporating 534 genetic variants in a training set of 2,872 patients with stroke and 2,494 controls. We then validated its association with incident stroke using Cox regression models in large Chinese population-based prospective cohorts comprising 41,006 individuals.

Results: During a total of 367,750 person-years (mean follow-up 9.0 years), 1,227 participants developed stroke before age 80 years. Individuals with high polygenic risk had an about 2-fold higher risk of incident stroke compared with those with low polygenic risk (hazard ratio [HR] 1.99, 95% confidence interval [CI] 1.66-2.38), with the lifetime risk of stroke being 25.2% (95% CI 22.5%-27.7%) and 13.6% (95% CI 11.6%-15.5%), respectively. Individuals with both high polygenic risk and family history displayed lifetime risk as high as 41.1% (95% CI 31.4%-49.5%). Individuals with high polygenic risk achieved greater benefits in terms of absolute risk reductions from adherence to ideal fasting blood glucose and total cholesterol than those with low polygenic risk. Maintaining favorable cardiovascular health (CVH) profile could substantially mitigate the increased risk conferred by high polygenic risk to the level of low polygenic risk (from 34.6% to 13.2%).

Conclusions: Our metaPRS has great potential for risk stratification of stroke and identification of individuals who may benefit more from maintaining ideal CVH.

Classification of evidence: This study provides Class I evidence that metaPRS is predictive of stroke risk.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study

MeSH terms

Adult
Aged
Asian People
Case-Control Studies
China / epidemiology
Cohort Studies
Female
Genetic Predisposition to Disease* / epidemiology
Genetic Predisposition to Disease* / genetics
Genome-Wide Association Study
Heart Disease Risk Factors*
Humans
Incidence
Male
Meta-Analysis as Topic
Middle Aged
Models, Statistical
Multifactorial Inheritance
Reproducibility of Results
Risk Assessment* / methods
Risk Assessment* / standards
Stroke / blood
Stroke / epidemiology*
Stroke / genetics*
Stroke / prevention & control